|
Volumn 15, Issue 9, 2008, Pages 633-634
|
Ocular gene therapy trials due to report this year: Keeping an eye on clinical trials in 2008
a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ISOMERASE;
PARVOVIRUS VECTOR;
PROTEIN RPE65;
UNCLASSIFIED DRUG;
CARRIER PROTEIN;
EYE PROTEIN;
RPE65 PROTEIN, HUMAN;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG SAFETY;
GENE MUTATION;
GENE REPLACEMENT THERAPY;
GENE TARGETING;
GENETIC HETEROGENEITY;
HUMAN;
LEBER CONGENITAL AMAUROSIS;
NONHUMAN;
NOTE;
PIGMENT EPITHELIUM;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN FUNCTION;
RETINA DEGENERATION;
TREATMENT OUTCOME;
VIRAL GENE DELIVERY SYSTEM;
VISUAL ACUITY;
ADENO ASSOCIATED VIRUS;
GENE THERAPY;
GENETIC TRANSDUCTION;
GENETICS;
METABOLISM;
METHODOLOGY;
RETINA DISEASE;
UNITED KINGDOM;
UNITED STATES;
CARRIER PROTEINS;
CLINICAL TRIALS AS TOPIC;
DEPENDOVIRUS;
EYE PROTEINS;
GENE THERAPY;
GREAT BRITAIN;
HUMANS;
PIGMENT EPITHELIUM OF EYE;
RETINAL DISEASES;
TRANSDUCTION, GENETIC;
UNITED STATES;
|
EID: 42149128771
PISSN: 09697128
EISSN: 14765462
Source Type: Journal
DOI: 10.1038/gt.2008.28 Document Type: Note |
Times cited : (10)
|
References (5)
|